US Drug Patent 8,592,434: Claim Scope, Exclusivity, Orange Book Status and Generic Risk

US Patent 8,592,434 protects a single-dose, prolonged-release mucoadhesive buccal tablet containing acyclovir for treating orofacial herpes, particularly recurrent herpes labialis in immunocompetent patients. The patent is directed to the combination of a 50 mg acyclovir dose, mucoadhesive delivery, sustained release, milk proteins, hydrophilic polymer, alkali metal alkylsulfate and binding agent. Its strongest commercial relevance is to Sitavig, the FDA-approved 50 mg acyclovir buccal tablet marketed for recurrent herpes labialis.

The patent's core term runs into 2027, subject to the official patent-term calculation and any applicable adjustment or disclaimer. A generic or competing product would face its greatest risk if it uses the claimed formulation and markets a single-dose buccal treatment for the claimed patient population.

What does US Patent 8,592,434 protect?

The patent protects a method of treatment rather than acyclovir as an active ingredient. Independent claim 1 requires all of the following:

Required element	Claim 1 requirement
Disease	Orofacial herpes
Patient	A patient suffering from orofacial herpes
Dosing	Only a single dose
Dosage form	Prolonged-release mucoadhesive buccal tablet
Acyclovir	50 to 200 mg
Diluent	1% to 75% by weight
Alkali metal alkylsulfate	1% to 10% by weight
Binding agent	0.1% to 5% by weight
Natural milk proteins	5% to 80% by weight
Hydrophilic polymer	5% to 80% by weight
Release function	Polymer must provide sustained release of acyclovir

The claim uses the transitional term "comprising." That generally permits additional inactive ingredients, excipients and processing components, provided the accused product still contains every required element.

The patent does not broadly cover every acyclovir tablet, every herpes treatment or every buccal dosage form. It is a formulation-and-use combination claim. A product can avoid literal infringement by omitting or materially changing a required element, such as the milk protein component, the alkali metal alkylsulfate, the single-dose regimen or the mucoadhesive buccal delivery system.

How do claims 2 through 22 narrow the patent scope?

The dependent claims create progressively narrower positions around the commercial formulation and the target patient population.

Dose and formulation limitations

Claims 2 and 7 limit the acyclovir content to 50 mg. Claim 8 is the principal composition-specific claim and requires:

50 mg acyclovir;
15% microcrystalline cellulose;
4.5% sodium lauryl sulfate;
0.4% polyvinylpyrrolidone;
20% milk protein concentrate; and
15% hydroxypropylmethyl cellulose.

Claim 8 is commercially important because it tracks the key excipient architecture associated with Sitavig. It is narrower than claim 1 but may be easier to test analytically if a competing tablet uses the same or substantially similar formula.

Claim 3 narrows the ranges for the principal excipient classes:

Component	Claim 1 range	Claim 3 range
Alkali metal alkylsulfate	1% to 10%	2% to 6%
Binding agent	0.1% to 5%	0.1% to 5%
Natural milk proteins	5% to 80%	10% to 40%
Hydrophilic polymer	5% to 80%	10% to 40%

Claim 4 specifies sodium lauryl sulfate. Claim 5 specifies hydroxypropylmethyl cellulose. Claim 6 specifies milk protein concentrate.

Patient and treatment limitations

Claims 9 and 10 cover nonvesicular symptoms of orofacial herpes. These symptoms can include the prodromal stage before visible vesicles develop, which is commercially significant because buccal acyclovir products are used at the first sign of recurrence.

Claims 11 and 12 limit the patient to an immunocompetent individual. Claims 13 and 14 require recurrent orofacial herpes. Claims 15 through 17 cover treatment outcomes:

reduced duration of an episode;
delayed recurrence; and
increased occurrence of aborted episodes.

Claims 18 and 19 broaden the milk-protein limitation by specifying milk protein concentrate or total milk proteins. Claims 20 through 22 narrow the hydrophilic polymer to a polysaccharide, cellulose-based polymer or cellulose ether.

What is the strongest infringement theory under US Patent 8,592,434?

The strongest literal infringement case would involve a product with the following profile:

A 50 mg acyclovir tablet.
A single-dose regimen.
Buccal placement against the gum or cheek.
Mucoadhesive retention.
Prolonged or sustained release.
Sodium lauryl sulfate in the claimed range.
Milk protein concentrate or total milk proteins.
Hydroxypropylmethyl cellulose or another claimed hydrophilic polymer.
A label directed to recurrent herpes labialis, including treatment at nonvesicular or prodromal symptoms.

A product matching claim 8 would present the clearest formulation risk. A product that uses a different mucoadhesive polymer but retains milk proteins, sodium lauryl sulfate and the single-dose buccal regimen could still fall within claim 1 or claims 3, 18 and 20 through 22, depending on the exact composition.

A product with no milk protein component would have a substantial literal-infringement defense because natural milk proteins are a required limitation of every asserted independent claim provided here. The doctrine of equivalents could still be raised, but the viability of that theory would depend on prosecution history, prior-art amendments and the technical role of milk proteins in the claimed tablet.

What formulations are protected by the patent?

The patent covers a broad formulation envelope but concentrates commercial protection around the following excipient classes:

Functional class	Exemplary claimed material	Technical role
Active ingredient	Acyclovir	Antiviral agent
Diluent	Microcrystalline cellulose	Tablet bulk and compressibility
Surfactant	Sodium lauryl sulfate	Wetting and release support
Binder	Polyvinylpyrrolidone	Granulation and tablet cohesion
Natural protein	Milk protein concentrate or total milk proteins	Mucoadhesion and formulation matrix
Hydrophilic polymer	Hydroxypropylmethyl cellulose	Sustained release and gel formation

The claim language does not require that the percentages total 100%. Other excipients may be present. Claim 8 therefore appears to define a partial formulation rather than a closed quantitative composition.

The combination of milk protein and hydrophilic polymer is a central limitation. A conventional acyclovir oral tablet, an acyclovir suspension, a conventional buccal tablet without milk protein, and a rapidly disintegrating oral formulation would generally fall outside the literal scope.

When does US Patent 8,592,434 lose exclusivity?

The patent's earliest priority is reported as March 30, 2007, with US Patent 8,592,434 issuing on November 26, 2013. On a standard 20-year term measured from the earliest effective nonprovisional filing date, the expected base expiration is March 30, 2027. The applicable expiration date should be confirmed against the USPTO Patent Term Adjustment and Patent Term Extension records and the current FDA Orange Book listing.[1][2]

Event	Date
Earliest reported priority	March 30, 2007
US patent grant	November 26, 2013
Expected base expiration	March 30, 2027
FDA approval of Sitavig	October 2013
Expected end of three-year regulatory exclusivity	October 2016
Expected patent-based loss of exclusivity	March 2027

A patent expiration date does not automatically authorize a generic launch before regulatory approval. Conversely, the end of FDA marketing exclusivity does not eliminate an unexpired formulation patent.

What is the Orange Book status of acyclovir buccal tablet products?

Sitavig was approved by the FDA as a 50 mg buccal tablet for the treatment of recurrent herpes labialis in immunocompetent adults.[3] Its regulatory profile differs from that of conventional oral acyclovir and valacyclovir products because the product uses a single-dose mucoadhesive delivery system.

The Orange Book is the relevant source for listed patents and exclusivity associated with an approved small-molecule product. US Patent 8,592,434 has been associated with the Sitavig product and is the principal patent risk for an ANDA applicant seeking to copy the protected buccal formulation.[2]

Acyclovir itself is not patent-protected as a new active ingredient. The relevant barrier is the delivery technology and treatment method. Generic oral acyclovir tablets and capsules therefore do not establish freedom to market a 50 mg mucoadhesive buccal product.

What FDA regulatory exclusivity applies to Sitavig?

Sitavig received approval under the 505(b)(2) framework, according to FDA product materials and approval documentation.[3] Because acyclovir was previously approved, the product did not receive new chemical entity exclusivity. The approval was associated with a period of three-year exclusivity based on new clinical investigations supporting the product's approval.

That exclusivity period would have expired in 2016. It did not prevent later applications from relying on the acyclovir reference product after the exclusivity period ended. The remaining commercial barrier is the patent estate and the technical difficulty of reproducing the buccal tablet's performance.

What Paragraph IV challenges and generic entry risks exist?

An ANDA applicant seeking approval for a product that references Sitavig would need to address the listed patent through one of the statutory certification routes. A Paragraph IV certification would allege that the patent is invalid, unenforceable or not infringed. A Section viii statement could be relevant only if the proposed label omits the patented method of use and the FDA determines that the remaining labeling supports approval.

The principal Paragraph IV attack points would likely include:

Obviousness

The applicant could argue that a skilled formulator would have combined acyclovir with a mucoadhesive polymer, milk protein, surfactant and binder to obtain a sustained-release buccal tablet. The patent holder would respond that the specific excipient combination and single-dose treatment produced a clinically meaningful result that was not predictable from the prior art.

Written description and enablement

The broad percentage ranges in claim 1 could be challenged if the specification does not adequately support the full breadth of the claimed combinations. The patent holder would rely on examples and formulation disclosure showing that the range produces the required sustained-release and mucoadhesive properties.

Indefiniteness

Potential issues include the boundaries of "prolonged release," "mucoadhesive," "natural milk proteins" and the functional phrase "provides a sustained release of acyclovir." The strength of such an argument would depend on the specification's test methods and claim-construction record.

Infringement avoidance

A generic developer could attempt to design around the patent by:

removing milk proteins;
replacing sodium lauryl sulfate with another surfactant;
using a non-cellulose release polymer;
changing the dosage regimen from one dose to multiple doses;
using a nonmucoadhesive buccal dosage form;
shifting to a different acyclovir strength; or
marketing only a non-buccal oral formulation.

The most difficult design-around is likely a product that retains the single-dose buccal concept while materially changing the excipient system. Claims 1, 3 and 20 through 22 provide overlapping coverage across broad and narrower polymer and excipient categories.

Which companies compete with the protected product?

The competitive market divides into three groups:

Product category	Representative products	Relationship to US 8,592,434
Protected buccal acyclovir	Sitavig	Directly relevant
Conventional acyclovir	Generic acyclovir tablets, capsules and suspensions	Generally outside the claimed dosage form
Oral prodrug therapy	Generic and branded valacyclovir	Competes clinically but uses a different active moiety and delivery route

Valacyclovir can compete with Sitavig for episodic herpes labialis treatment without practicing the claimed buccal formulation. It does not, by itself, create a patent conflict under the claims supplied.

The product's commercial differentiation depends on single-dose administration, localized buccal retention and use at the first symptoms of recurrence. A conventional oral antiviral may offer a lower-cost substitute even when it does not infringe the patent.

How strong is the patent estate for acyclovir buccal delivery?

The estate is strongest against an exact or near-exact copy of the protected product. Its strengths are:

a specific commercial dosage form;
a single-dose treatment limitation;
detailed excipient classes;
a narrow 50 mg embodiment;
claims directed to recurrent herpes labialis and prodromal symptoms; and
dependent claims identifying the likely commercial ingredients.

Its limitations are equally material:

it does not cover acyclovir generally;
it does not cover ordinary oral tablets or valacyclovir;
every independent method claim requires natural milk proteins;
the claims require a single dose;
some treatment-outcome claims may create proof issues; and
the patent term ends in 2027 under the reported priority date.

The estate therefore has high product-specific strength but limited platform breadth.

What patent litigation or settlement agreements affect the product?

The cited patent and FDA materials establish the patent, product and regulatory relationship but do not establish a reported final judgment invalidating US Patent 8,592,434 or a public settlement authorizing an earlier generic launch. No specific Paragraph IV judgment or settlement is identified in the sources cited here.

The practical litigation question would center on whether an ANDA product contains the claimed milk-protein and sustained-release architecture. A formulation that omits those components would shift the dispute toward validity and doctrine-of-equivalents issues rather than straightforward claim overlap.

What revenue exposure does the patent create?

The patent creates direct exposure for the branded acyclovir buccal product and indirect exposure for any generic that seeks to duplicate its commercial positioning. It does not block the broader acyclovir or herpes-antiviral market.

Revenue risk is therefore concentrated in:

sales of the 50 mg buccal product;
premium pricing attributable to single-dose administration;
prescriptions for recurrent herpes labialis; and
market share that could shift to an authorized or generic buccal substitute after patent expiry.

Conventional acyclovir and valacyclovir generics limit the product's pricing power before patent expiry because physicians and patients have lower-cost alternatives.

Key Takeaways

US Patent 8,592,434 is a formulation-and-method patent, not an acyclovir composition-of-matter patent.
Claim 1 requires a single dose of a prolonged-release mucoadhesive buccal tablet containing acyclovir, natural milk proteins, a hydrophilic polymer, an alkali metal alkylsulfate, a binder and a diluent.
Claim 8 is the closest claim to the commercial 50 mg formulation, including milk protein concentrate, sodium lauryl sulfate, polyvinylpyrrolidone, microcrystalline cellulose and hydroxypropylmethyl cellulose.
Sitavig is the principal FDA product associated with the patent.
The reported expected patent expiration is March 30, 2027, subject to official USPTO and Orange Book term records.
The greatest generic risk arises from an exact or near-exact copy of the single-dose buccal formulation.
Conventional acyclovir and valacyclovir products generally do not practice the claimed dosage form.
A design-around that removes milk proteins or changes the single-dose mucoadhesive architecture could materially reduce literal infringement risk.
The FDA exclusivity period ended years before the expected patent expiration, leaving the patent as the principal listed barrier.

FAQs

Can a generic acyclovir tablet infringe US Patent 8,592,434?

Generally, no. A conventional oral acyclovir tablet does not meet the buccal, mucoadhesive, prolonged-release and single-dose limitations.

Does the patent cover valacyclovir?

No. The claims identify acyclovir as the active ingredient and do not cover valacyclovir as a different active moiety.

Is milk protein required for infringement?

For the claims supplied, natural milk proteins are required. A product that contains no natural milk proteins has a strong noninfringement position against the literal wording of the independent claims.

Can a competing product use a different mucoadhesive polymer?

Potentially. A different polymer could avoid narrower claims directed to cellulose polymers or hydroxypropylmethyl cellulose. Claim 1 remains relevant if the substitute is a hydrophilic polymer that provides sustained release.

Can a generic launch before March 2027?

Only if it obtains approval through a pathway that resolves or avoids the listed patent, reaches an authorized settlement or license, successfully defeats the patent, or markets a product that does not infringe the applicable claims.

References

United States Patent and Trademark Office. (2013). US Patent No. 8,592,434, treatment of orofacial herpes with a single-dose prolonged-release mucoadhesive buccal tablet.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2013). Sitavig (acyclovir) buccal tablet prescribing information and approval materials. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ligand Pharms	SITAVIG	acyclovir	TABLET;BUCCAL	203791-001	Apr 12, 2013		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF HERPES LABIALIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2782779	⤷ Start Trial
China	102652016	⤷ Start Trial
Denmark	2509586	⤷ Start Trial
European Patent Office	2335690	⤷ Start Trial
European Patent Office	2509586	⤷ Start Trial
Spain	2678122	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,592,434

Which drugs does patent 8,592,434 protect, and when does it expire?

Summary for Patent: 8,592,434